Nasus Pharma to Present Positive Clinical Results from Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting
Click here
Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis
Click Here
Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine
Click Here
Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice
CLICK HERE
Nasus pharma presented clinical results at Fourth Annual – ASPN Conference, July 14-17, Miami Beach
CLICK HERE
Nasus Pharma presented clinical results of intranasal epinephrine in EAACI, July 2022, Prague
A Novel Faster‑Acting, Dry Powder‑Based, Naloxone Intranasal Formulation for Opioid Overdose
Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan®
A Novel Faster‑Acting, Dry Powder‑Based, Naloxone Intranasal Formulation for Opioid Overdose
Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in
Results demonstrate rapid epinephrine absorption- for potentially quicker rescue ofpatients in anaphylactic shock Tel Aviv Israel June 23 2021– Nasus Pharma Ltd a clinical-stage biopharmaceuticalcompany focused on developing needle-free, powder-based Intranasal (PBI) specializedproduct portfolio, to address acute medical conditions announced positive results froma pilot trial of intranasal powder-based Epinephrine. FMXIN002 is an investigational intranasal epinephrine […]
Nasus Pharma announces positive Results in Naloxone Pivotal Trial.
Nasus Pharma Announces Positive Results in Pivotal Trial of FMXIN001 Naloxone Powder-Based Nasal Spray for the Treatment of opioid overdose • Significantly higher rapid absorption of Naloxone – may be critical to rescue of over-dose victims. • Excellent safety profile. • NDA submission planned for later this year. Tel Aviv Israel April 13 2021 […]